PPARG and breast cancer: For example, it downregulates ERK1/2 through PPARγ in MCF-7 breast cancer cells [131], and inhibits the Akt/GSK-3β survival pathway by activating PTEN in SKBR3 and T47D breast cancer cell lines [132].